Development of Innovative Multistage Nanovectors for Cancer Immunotherapy

Flavia Fontana, Mohammad-Ali Shahbazi, Dongfei Liu, Hongbo Zhang, Ermei Mäkilä, Jarno Salonen, Jouni Tapio Hirvonen, Helder Almeida Santos

Research output: Conference materialsAbstractResearchpeer-review

Abstract

Introduction Cancers are is a very challenging diseases and new approaches are sought to help in their its treatment. Cancer immunotherapy involves the patient’s own immune system in the fight against the tumors using antibodies directed to the so-called “check-point inhibitors” or by the administration of chimeric T-lymphocytes. It is envisaged that the administration of nanoparticles in cancer vaccines would lead to a decrease in the side effects of the drugs, helping targeted drug delivery, and increase increasing the efficacy of the therapy due to the adjuvant properties of the particles themselves [1]. Porous silicon (PSi) is a biocompatible porous material which presents adjuvant-like properties [2]. Acetylated dextran (AcDX) and spermine-modified AcDX (SpAcDX) are chemically-modified polymers derived from dextran, a FDA approved material, able to stimulate an immune response by the activation of Toll-like receptors [3]. Methods Multistage nanovectors were prepared by nanoprecipitation during glass capillary microfluidics [4]. PSi nanoparticles were encapsulated in a polymeric matrix made of AcDEX. The immunostimulant properties of the nanoparticles were assessed in vitro on human immortalized immune cells and blood-derived monocytes . Results The developed nanosystems induced the expression of co-stimulatory factors (CD86) in, for example, peripheral blood monocytes (Fig.1). Figure 1 Percentage of CD86+ expression in a population of human peripheral blood monocytes after 72 h of incubation with the particles. TOPSi@AcDX are thermally oxidized PSi particles encapsulated inside an AcDEX shell; TOPSi@SpAcDX particles were encapsulated inside a spermine-modifed AcDEX shell; TOPSi@AcDX@CCM particles were further modified with membranes derived from MDA-MB-231 cancer cells. The levels of significance were set at p>0.05 (*) and p>0.01 (**); n = 3. Discussion The multistage nanovectors, produced with different polymers, promoted the expression of CD86 from human monocytes , KG 1, and BDCM (results not shown). Moreover, the system modified with membranes derived from cancer cells showed the highest levels of CDs stimulation, with a statistically significant difference compared to the particles with the polymer alone. Conclusions The developed systems promoted the expression of costimulatory factors (CD80) confirming their adjuvant properties that make them suitable platforms for further development as cancer vaccines. References [1] D.J. Irvine,M.C. Hanson, Synthetic Nanoparticles for Vaccines and Immunotherapy,115 Chemical Reviews (2015), 11109-46. [2] M.A. Shahbazi,T.D. Fernandez, Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms, Biomaterials 35 (33)(2014), 9224-35. [3] L. Cui,J.A. Cohen, Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting, Bioconjug Chem 22 (5)(2011), 949-57. [4] D. Liu,S. Cito, A versatile and robust microfluidic platform toward high throughput synthesis of homogeneous nanoparticles with tunable properties, Adv Mater 27 (14)(2015), 2298-304. Acknowledgements Financial support from the Academy of Finland (Grants No. 252215 and 281300), the University of Helsinki Research Funds, the Biocentrum Helsinki, and the European Research Council (FP/2007-2013, Grant 310892) is greatly acknowledge.
Original languageEnglish
Publication statusPublished - 30 Sep 2016
EventInternational Conference on Nanomedicine and Nanobiotechnology - University Pierre and Marie Curie, Paris, France
Duration: 28 Sep 201630 Sep 2016
http://premc.org/iconan2016/

Conference

ConferenceInternational Conference on Nanomedicine and Nanobiotechnology
Abbreviated titleICONAN 2016
CountryFrance
CityParis
Period28/09/201630/09/2016
Internet address

Fields of Science

  • 317 Pharmacy
  • Nanotechnology
  • vaccine
  • cancer immunotherapy
  • biohybrid

Cite this

Fontana, F., Shahbazi, M-A., Liu, D., Zhang, H., Mäkilä, E., Salonen, J., ... Almeida Santos, H. (2016). Development of Innovative Multistage Nanovectors for Cancer Immunotherapy. Abstract from International Conference on Nanomedicine and Nanobiotechnology, Paris, France.
Fontana, Flavia ; Shahbazi, Mohammad-Ali ; Liu, Dongfei ; Zhang, Hongbo ; Mäkilä, Ermei ; Salonen, Jarno ; Hirvonen, Jouni Tapio ; Almeida Santos, Helder. / Development of Innovative Multistage Nanovectors for Cancer Immunotherapy. Abstract from International Conference on Nanomedicine and Nanobiotechnology, Paris, France.
@conference{b0157cb450a44fad9e666268a640db57,
title = "Development of Innovative Multistage Nanovectors for Cancer Immunotherapy",
abstract = "Introduction Cancers are is a very challenging diseases and new approaches are sought to help in their its treatment. Cancer immunotherapy involves the patient’s own immune system in the fight against the tumors using antibodies directed to the so-called “check-point inhibitors” or by the administration of chimeric T-lymphocytes. It is envisaged that the administration of nanoparticles in cancer vaccines would lead to a decrease in the side effects of the drugs, helping targeted drug delivery, and increase increasing the efficacy of the therapy due to the adjuvant properties of the particles themselves [1]. Porous silicon (PSi) is a biocompatible porous material which presents adjuvant-like properties [2]. Acetylated dextran (AcDX) and spermine-modified AcDX (SpAcDX) are chemically-modified polymers derived from dextran, a FDA approved material, able to stimulate an immune response by the activation of Toll-like receptors [3]. Methods Multistage nanovectors were prepared by nanoprecipitation during glass capillary microfluidics [4]. PSi nanoparticles were encapsulated in a polymeric matrix made of AcDEX. The immunostimulant properties of the nanoparticles were assessed in vitro on human immortalized immune cells and blood-derived monocytes . Results The developed nanosystems induced the expression of co-stimulatory factors (CD86) in, for example, peripheral blood monocytes (Fig.1). Figure 1 Percentage of CD86+ expression in a population of human peripheral blood monocytes after 72 h of incubation with the particles. TOPSi@AcDX are thermally oxidized PSi particles encapsulated inside an AcDEX shell; TOPSi@SpAcDX particles were encapsulated inside a spermine-modifed AcDEX shell; TOPSi@AcDX@CCM particles were further modified with membranes derived from MDA-MB-231 cancer cells. The levels of significance were set at p>0.05 (*) and p>0.01 (**); n = 3. Discussion The multistage nanovectors, produced with different polymers, promoted the expression of CD86 from human monocytes , KG 1, and BDCM (results not shown). Moreover, the system modified with membranes derived from cancer cells showed the highest levels of CDs stimulation, with a statistically significant difference compared to the particles with the polymer alone. Conclusions The developed systems promoted the expression of costimulatory factors (CD80) confirming their adjuvant properties that make them suitable platforms for further development as cancer vaccines. References [1] D.J. Irvine,M.C. Hanson, Synthetic Nanoparticles for Vaccines and Immunotherapy,115 Chemical Reviews (2015), 11109-46. [2] M.A. Shahbazi,T.D. Fernandez, Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms, Biomaterials 35 (33)(2014), 9224-35. [3] L. Cui,J.A. Cohen, Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting, Bioconjug Chem 22 (5)(2011), 949-57. [4] D. Liu,S. Cito, A versatile and robust microfluidic platform toward high throughput synthesis of homogeneous nanoparticles with tunable properties, Adv Mater 27 (14)(2015), 2298-304. Acknowledgements Financial support from the Academy of Finland (Grants No. 252215 and 281300), the University of Helsinki Research Funds, the Biocentrum Helsinki, and the European Research Council (FP/2007-2013, Grant 310892) is greatly acknowledge.",
keywords = "317 Pharmacy, Nanotechnology, vaccine, cancer immunotherapy, biohybrid",
author = "Flavia Fontana and Mohammad-Ali Shahbazi and Dongfei Liu and Hongbo Zhang and Ermei M{\"a}kil{\"a} and Jarno Salonen and Hirvonen, {Jouni Tapio} and {Almeida Santos}, Helder",
year = "2016",
month = "9",
day = "30",
language = "English",
note = "International Conference on Nanomedicine and Nanobiotechnology, ICONAN 2016 ; Conference date: 28-09-2016 Through 30-09-2016",
url = "http://premc.org/iconan2016/",

}

Fontana, F, Shahbazi, M-A, Liu, D, Zhang, H, Mäkilä, E, Salonen, J, Hirvonen, JT & Almeida Santos, H 2016, 'Development of Innovative Multistage Nanovectors for Cancer Immunotherapy' International Conference on Nanomedicine and Nanobiotechnology, Paris, France, 28/09/2016 - 30/09/2016, .

Development of Innovative Multistage Nanovectors for Cancer Immunotherapy. / Fontana, Flavia; Shahbazi, Mohammad-Ali; Liu, Dongfei; Zhang, Hongbo; Mäkilä, Ermei; Salonen, Jarno ; Hirvonen, Jouni Tapio; Almeida Santos, Helder.

2016. Abstract from International Conference on Nanomedicine and Nanobiotechnology, Paris, France.

Research output: Conference materialsAbstractResearchpeer-review

TY - CONF

T1 - Development of Innovative Multistage Nanovectors for Cancer Immunotherapy

AU - Fontana, Flavia

AU - Shahbazi, Mohammad-Ali

AU - Liu, Dongfei

AU - Zhang, Hongbo

AU - Mäkilä, Ermei

AU - Salonen, Jarno

AU - Hirvonen, Jouni Tapio

AU - Almeida Santos, Helder

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Introduction Cancers are is a very challenging diseases and new approaches are sought to help in their its treatment. Cancer immunotherapy involves the patient’s own immune system in the fight against the tumors using antibodies directed to the so-called “check-point inhibitors” or by the administration of chimeric T-lymphocytes. It is envisaged that the administration of nanoparticles in cancer vaccines would lead to a decrease in the side effects of the drugs, helping targeted drug delivery, and increase increasing the efficacy of the therapy due to the adjuvant properties of the particles themselves [1]. Porous silicon (PSi) is a biocompatible porous material which presents adjuvant-like properties [2]. Acetylated dextran (AcDX) and spermine-modified AcDX (SpAcDX) are chemically-modified polymers derived from dextran, a FDA approved material, able to stimulate an immune response by the activation of Toll-like receptors [3]. Methods Multistage nanovectors were prepared by nanoprecipitation during glass capillary microfluidics [4]. PSi nanoparticles were encapsulated in a polymeric matrix made of AcDEX. The immunostimulant properties of the nanoparticles were assessed in vitro on human immortalized immune cells and blood-derived monocytes . Results The developed nanosystems induced the expression of co-stimulatory factors (CD86) in, for example, peripheral blood monocytes (Fig.1). Figure 1 Percentage of CD86+ expression in a population of human peripheral blood monocytes after 72 h of incubation with the particles. TOPSi@AcDX are thermally oxidized PSi particles encapsulated inside an AcDEX shell; TOPSi@SpAcDX particles were encapsulated inside a spermine-modifed AcDEX shell; TOPSi@AcDX@CCM particles were further modified with membranes derived from MDA-MB-231 cancer cells. The levels of significance were set at p>0.05 (*) and p>0.01 (**); n = 3. Discussion The multistage nanovectors, produced with different polymers, promoted the expression of CD86 from human monocytes , KG 1, and BDCM (results not shown). Moreover, the system modified with membranes derived from cancer cells showed the highest levels of CDs stimulation, with a statistically significant difference compared to the particles with the polymer alone. Conclusions The developed systems promoted the expression of costimulatory factors (CD80) confirming their adjuvant properties that make them suitable platforms for further development as cancer vaccines. References [1] D.J. Irvine,M.C. Hanson, Synthetic Nanoparticles for Vaccines and Immunotherapy,115 Chemical Reviews (2015), 11109-46. [2] M.A. Shahbazi,T.D. Fernandez, Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms, Biomaterials 35 (33)(2014), 9224-35. [3] L. Cui,J.A. Cohen, Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting, Bioconjug Chem 22 (5)(2011), 949-57. [4] D. Liu,S. Cito, A versatile and robust microfluidic platform toward high throughput synthesis of homogeneous nanoparticles with tunable properties, Adv Mater 27 (14)(2015), 2298-304. Acknowledgements Financial support from the Academy of Finland (Grants No. 252215 and 281300), the University of Helsinki Research Funds, the Biocentrum Helsinki, and the European Research Council (FP/2007-2013, Grant 310892) is greatly acknowledge.

AB - Introduction Cancers are is a very challenging diseases and new approaches are sought to help in their its treatment. Cancer immunotherapy involves the patient’s own immune system in the fight against the tumors using antibodies directed to the so-called “check-point inhibitors” or by the administration of chimeric T-lymphocytes. It is envisaged that the administration of nanoparticles in cancer vaccines would lead to a decrease in the side effects of the drugs, helping targeted drug delivery, and increase increasing the efficacy of the therapy due to the adjuvant properties of the particles themselves [1]. Porous silicon (PSi) is a biocompatible porous material which presents adjuvant-like properties [2]. Acetylated dextran (AcDX) and spermine-modified AcDX (SpAcDX) are chemically-modified polymers derived from dextran, a FDA approved material, able to stimulate an immune response by the activation of Toll-like receptors [3]. Methods Multistage nanovectors were prepared by nanoprecipitation during glass capillary microfluidics [4]. PSi nanoparticles were encapsulated in a polymeric matrix made of AcDEX. The immunostimulant properties of the nanoparticles were assessed in vitro on human immortalized immune cells and blood-derived monocytes . Results The developed nanosystems induced the expression of co-stimulatory factors (CD86) in, for example, peripheral blood monocytes (Fig.1). Figure 1 Percentage of CD86+ expression in a population of human peripheral blood monocytes after 72 h of incubation with the particles. TOPSi@AcDX are thermally oxidized PSi particles encapsulated inside an AcDEX shell; TOPSi@SpAcDX particles were encapsulated inside a spermine-modifed AcDEX shell; TOPSi@AcDX@CCM particles were further modified with membranes derived from MDA-MB-231 cancer cells. The levels of significance were set at p>0.05 (*) and p>0.01 (**); n = 3. Discussion The multistage nanovectors, produced with different polymers, promoted the expression of CD86 from human monocytes , KG 1, and BDCM (results not shown). Moreover, the system modified with membranes derived from cancer cells showed the highest levels of CDs stimulation, with a statistically significant difference compared to the particles with the polymer alone. Conclusions The developed systems promoted the expression of costimulatory factors (CD80) confirming their adjuvant properties that make them suitable platforms for further development as cancer vaccines. References [1] D.J. Irvine,M.C. Hanson, Synthetic Nanoparticles for Vaccines and Immunotherapy,115 Chemical Reviews (2015), 11109-46. [2] M.A. Shahbazi,T.D. Fernandez, Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms, Biomaterials 35 (33)(2014), 9224-35. [3] L. Cui,J.A. Cohen, Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting, Bioconjug Chem 22 (5)(2011), 949-57. [4] D. Liu,S. Cito, A versatile and robust microfluidic platform toward high throughput synthesis of homogeneous nanoparticles with tunable properties, Adv Mater 27 (14)(2015), 2298-304. Acknowledgements Financial support from the Academy of Finland (Grants No. 252215 and 281300), the University of Helsinki Research Funds, the Biocentrum Helsinki, and the European Research Council (FP/2007-2013, Grant 310892) is greatly acknowledge.

KW - 317 Pharmacy

KW - Nanotechnology

KW - vaccine

KW - cancer immunotherapy

KW - biohybrid

M3 - Abstract

ER -

Fontana F, Shahbazi M-A, Liu D, Zhang H, Mäkilä E, Salonen J et al. Development of Innovative Multistage Nanovectors for Cancer Immunotherapy. 2016. Abstract from International Conference on Nanomedicine and Nanobiotechnology, Paris, France.